Steven Μ. Albelda

46.7k citations

315 papers · 35.5k indexed · 20 hit papers · h-index 96

Immunology top 0.05%
Oncology top 0.05%
Molecular Biology top 0.2%
Immunology and Allergy top 0.02%
Pulmonary and Respiratory Medicine top 0.2%

Co-authors: Clayton A. Buck Veena Kapoor Zvi G. Fridlender Jing Sun Edmund K. Moon Larry R. Kaiser Peter J. Newman Guanjun Cheng
Topics: Cell Adhesion Molecules Research (71 papers)Virus-based gene therapy research (47 papers)Occupational and environmental lung diseases (42 papers)
Cited by: Immunology and Allergy Immunology Oncology
Journals: Science Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States United Kingdom Israel

In The Last Decade

Steven Μ. Albelda

313 papers receiving 34.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN

2009 2.6k citations Jing Sun, Samuel Kim et al. profile →
Integrins and other cell adhesion molecules

1990 1.6k citations Steven Μ. Albelda et al. profile →
Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

2005 848 citations Veena Kapoor, Larry R. Kaiser et al. Clinical Cancer Research profile →
BRAF and RAS mutations in human lung cancer and melanoma.

2002 841 citations Marcia S. Brose, Steven Μ. Albelda et al. PubMed profile →
Adhesion molecules and inflammatory injury

1994 834 citations Steven Μ. Albelda et al. profile →
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

2013 693 citations Gregory L. Beatty, Andrew R. Haas et al. Cancer Immunology Research profile →
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

2009 690 citations Carmine Carpenito, Michael C. Milone et al. profile →
Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response

2007 679 citations Steven Μ. Albelda et al. profile →
CAR T Cell Therapy for Solid Tumors

2016 663 citations Kheng Newick, Shaun O’Brien et al. profile →
Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule.

1991 619 citations Steven Μ. Albelda et al. profile →
Tumor-associated neutrophils: friend or foe?

2012 542 citations Steven Μ. Albelda et al. profile →
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity

2013 515 citations Liang‐Chuan S. Wang, Albert Lo et al. Cancer Immunology Research profile →
Integrin adhesion molecules in the human endometrium. Correlation with the normal and abnormal menstrual cycle.

1992 508 citations Steven Μ. Albelda et al. profile →
Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.

2001 506 citations Steven Μ. Albelda et al. PubMed profile →
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer

2014 495 citations Evgeniy Eruslanov, Anjana Ranganathan et al. profile →
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

2013 476 citations Marcela V. Maus, Andrew R. Haas et al. Cancer Immunology Research profile →
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

2011 447 citations Edmund K. Moon, Carmine Carpenito et al. Clinical Cancer Research profile →
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells

2015 407 citations Albert Lo, Liang‐Chuan S. Wang et al. Cancer Research profile →
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

2023 250 citations Steven Μ. Albelda profile →
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

2023 129 citations Zebin Xiao, Leslie Todd et al. profile →

Peers

Countries citing papers authored by Steven Μ. Albelda

Since Specialization

Citations

This map shows the geographic impact of Steven Μ. Albelda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Μ. Albelda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Μ. Albelda more than expected).

Fields of papers citing papers by Steven Μ. Albelda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Μ. Albelda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Μ. Albelda. The network helps show where Steven Μ. Albelda may publish in the future.

Co-authorship network of co-authors of Steven Μ. Albelda

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Μ. Albelda. A scholar is included among the top collaborators of Steven Μ. Albelda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Μ. Albelda. Steven Μ. Albelda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A fibroblast activation protein targeted optical tracer for identifying primary and metastatic sarcoma during resection 2025 ·EJNMMI Research ·Feredun Azari,Gregory T. Kennedy,Ian W. Folkert,(unknown),(unknown),Andrew Conner,Elizabeth Bernstein,(unknown),Neil T. Sullivan,Evgeniy Eruslanov,Steven Μ. Albelda,Philip S. Low,(unknown)	1
2	Molecular Imaging in Precision-Cut Non-Small Cell Lung Cancer Slices 2023 ·The Annals of Thoracic Surgery ·Feredun Azari,Gregory T. Kennedy,(unknown),Philip S. Low,Maria C. Basil,Joseph D. Planer,Jeremy Katzen,Evgeniy Eruslanov,Steven Μ. Albelda,Sunil Singhal	5
3	Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy 2023 ·Cancer Research Communications ·Richard W. Davis,Astero Klampatsa,Gwendolyn M. Cramer,Michele M. Kim,Joann M. Miller,(unknown),(unknown),(unknown),Mary Putt,Sergei A. Vinogradov,Steven Μ. Albelda,Keith A. Cengel,Theresa M. Busch	1
4	Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74 2022 ·Clinical Cancer Research ·(unknown),Estela Noguera-Ortega,Zebin Xiao,Leslie Todd,John Scholler,Decheng Song,Maria Liousia,(unknown),Kexiang Xu,Kimberly J. Edwards,Michael D. Farwell,Carl H. June,Steven Μ. Albelda,Ellen Puré,Mark A. Sellmyer	34
5	Na+/H+-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells 2022 ·Cancer Research Communications ·(unknown),Hongguang Shao,(unknown),Patricia Brafford,Zachary E. Stine,Jing Sun,Dean W. Felsher,Jordan S. Orange,Steven Μ. Albelda,Chi V. Dang	1
6	Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes 2019 ·OncoImmunology ·Astero Klampatsa,Shaun O’Brien,Jeffrey C. Thompson,Abhishek Rao,Jason Stadanlick,Marina C. Martinez,Maria Liousia,Edward Cantu,Keith A. Cengel,Edmund K. Moon,Sunil Singhal,Evgeniy Eruslanov,Steven Μ. Albelda	34
7	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC 2019 ·JCI Insight ·Julia Kargl,Xiaodong Zhu,Huajia Zhang,Grace Yang,Travis J. Friesen,(unknown),Dean Y. Maeda,John A. Zebala,Jill McKay-Fleisch,Gavin Meredith,Afshin Mashadi-Hossein,Christina S. Baik,Robert H. Pierce,Mary W. Redman,Jeffrey C. Thompson,Steven Μ. Albelda,Hamid Bolouri,A. McGarry Houghton	127
8	Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization 2016 ·Cancer Immunology Research ·Kheng Newick,Shaun O’Brien,Jing Sun,Veena Kapoor,(unknown),Albert Lo,Ellen Puré,Edmund K. Moon,Steven Μ. Albelda	160
9	Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer 2015 ·Clinical Cancer Research ·Edmund K. Moon,Raghuveer Ranganathan,Evgeniy Eruslanov,Soyeon Kim,Kheng Newick,Shaun O’Brien,Albert Lo,Xiaojun Liu,Yangbing Zhao,Steven Μ. Albelda	96
10	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors 2014 ·Clinical Cancer Research ·Edmund K. Moon,Liang-Chuan Wang,Douglas V. Dolfi,Caleph B. Wilson,Raghuveer Ranganathan,Jing Sun,Veena Kapoor,John Scholler,Ellen Puré,Michael C. Milone,Carl H. June,James L. Riley,E. John Wherry,Steven Μ. Albelda	344
11	Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases 2013 ·Cancer Research ·Matthew J. Riese,Liang‐Chuan S. Wang,Edmund K. Moon,Rohan P. Joshi,Anjana Ranganathan,Carl H. June,Gary A. Koretzky,Steven Μ. Albelda	106
12	Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignanciesbreakdown → 2013 ·Cancer Immunology Research ·Gregory L. Beatty,Andrew R. Haas,Marcela V. Maus,Drew A. Torigian,Michael C. Soulen,Gabriela Plesa,Anne Chew,Yangbing Zhao,Bruce L. Levine,Steven Μ. Albelda,Michael Kalos,Carl H. June	693
13	Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System 2011 ·Clinical Cancer Research ·Andrew V. Kossenkov,Anil Vachani,Celia Chang,Calen Nichols,(unknown),Wen-Hwai Horng,William N. Rom,Steven Μ. Albelda,Michael K. Showe,Louise C. Showe	42
14	Progression of Human Bronchioloalveolar Carcinoma to Invasive Adenocarcinoma Is Modeled in a Transgenic Mouse Model of K-ras–Induced Lung Cancer by Loss of the TGF-β Type II Receptor 2011 ·Cancer Research ·Alain Borczuk,(unknown),Ping Lü,Jinli Chen,(unknown),Richard A. Friedman,Steven Μ. Albelda,Charles A. Powell	28
15	Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptorbreakdown → 2011 ·Clinical Cancer Research ·Edmund K. Moon,Carmine Carpenito,Jing Sun,Liang‐Chuan S. Wang,Veena Kapoor,Jarrod D. Predina,Daniel J. Powell,James L. Riley,Carl H. June,Steven Μ. Albelda	447
16	Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor 2010 ·Cancer Research ·Yangbing Zhao,Edmund K. Moon,Carmine Carpenito,Chrystal M. Paulos,Xiaojun Liu,Andrea Brennan,Anne Chew,Richard G. Carroll,John Scholler,Bruce L. Levine,Steven Μ. Albelda,Carl H. June	366
17	Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with Non–Small Cell Lung Cancer from Patients with Nonmalignant Lung Disease 2009 ·Cancer Research ·Michael K. Showe,Anil Vachani,Andrew V. Kossenkov,Malik Yousef,Calen Nichols,Elena V. Nikonova,Celia Chang,John C. Kucharczuk,(unknown),Elliot Wakeam,(unknown),David J. Speicher,William N. Rom,Steven Μ. Albelda,Louise C. Showe	125
18	Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy 2008 ·Cancer Research ·Samuel Kim,George Buchlis,Zvi G. Fridlender,Jing Sun,Veena Kapoor,Guanjun Cheng,Andrew R. Haas,Hung Kam Cheung,Xiamei Zhang,Michael J. Corbley,Larry R. Kaiser,Leona Ling,Steven Μ. Albelda	71
19	A 10-Gene Classifier for Distinguishing Head and Neck Squamous Cell Carcinoma and Lung Squamous Cell Carcinoma 2007 ·Clinical Cancer Research ·Anil Vachani,Michael Nebozhyn,Sunil Singhal,(unknown),Elliot Wakeam,Ruth J. Muschel,Charles A. Powell,Patrick M. Gaffney,Bhuvanesh Singh,Marcia S. Brose,Leslie A. Litzky,John C. Kucharczuk,Larry R. Kaiser,J. S. Marron,Michael K. Showe,Steven Μ. Albelda,Louise C. Showe	50
20	Gene expression profiling of malignant mesothelioma. 2003 ·PubMed ·Sunil Singhal,Rainer Wiewrodt,(unknown),Kunjlata M. Amin,(unknown),Joseph S. Friedberg,John C. Kucharczuk,Leslie A. Litzky,Steven W. Johnson,Larry R. Kaiser,Steven Μ. Albelda	107

About Steven Μ. Albelda

Steven Μ. Albelda is a scholar working on Immunology and Allergy, Immunology and Biotechnology, having authored 315 papers that have together received 35.5k indexed citations. Recurring topics across this work include Cell Adhesion Molecules Research (71 papers), Virus-based gene therapy research (47 papers) and Occupational and environmental lung diseases (42 papers). The work is most often cited by research in Immunology and Allergy (5.7k citations), Immunology (13.6k citations) and Oncology (13.2k citations). Steven Μ. Albelda has collaborated with scholars based in United States, United Kingdom and Israel. Frequent co-authors include Clayton A. Buck, Veena Kapoor, Zvi G. Fridlender, Jing Sun, Edmund K. Moon, Larry R. Kaiser, Peter J. Newman, Guanjun Cheng, Carl H. June and Sunil Singhal. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact